RESUMO
Summary: Objective. To evaluate the tolerability and efficacy of Dermatophagoides pteronyssinus/Dermatophagoides farinae mixture subcutaneous immunotherapy (SCIT). Methods. Patients received an abbreviated build-up schedule. The aims were: number, percentage, and severity of adverse reactions. Secondary outcomes included: changes in immunoglobulin titers and changes in dose-response skin prick tests. Results. Out of 289 administrations, 17% elicited any clinically relevant adverse reaction. Most of them were local reactions (LR) (9.4%) and the rest (7.6%) were systemic. Significant increases in sIgG and sIgG4 were detected in serum samples. Cutaneous reactivity decreased significantly. Conclusions. SCIT with house dust mites mixture of ROXALL Medicina España S.A. seems to have an acceptable tolerability profile, induces blocking IgG and decreases skin reactivity.
Assuntos
Imunoterapia/métodos , Ácaros/imunologia , Pyroglyphidae/imunologia , Testes Cutâneos/métodos , Adulto , Alérgenos , Animais , Antígenos de Dermatophagoides , Feminino , Humanos , Masculino , EspanhaRESUMO
Summary: Objectives. To evaluate the tolerability and efficacy of Olea europaea subcutaneous immunotherapy (SCIT) on patients with rhinoconjunctivitis. Methods. In this open clinical trial patients were assigned to an abbreviated build-up scheme. The outcomes were: number, percentage, and severity of adverse reactions. Secondary outcomes included: changes in immunoglobulin titers and changes in dose-response skin prick tests. Results. Only 8 systemic reactions were registered, which represented 7/47 (14.9%) of patients and 8/429 (1.9%) of administered doses. Regarding immunological parameters the significant increases of sIgG and sIgG4 evidenced the changes in the patient immune system. Cutaneous reactivity decreased significantly. Conclusions. Olea europaea SCIT (Allergovac® depot ROXALL Medicina España S.A.) showed a good safety and tolerability profile. Immunological changes with induction of blocking IgG and decreases in cutaneous reactivity were detected in the patients.
Assuntos
Alérgenos/imunologia , Antígenos de Plantas/imunologia , Conjuntivite Alérgica/terapia , Dessensibilização Imunológica/métodos , Extratos Vegetais/imunologia , Rinite/terapia , Pele/imunologia , Adulto , Protocolos Clínicos , Conjuntivite Alérgica/imunologia , Preparações de Ação Retardada , Feminino , Humanos , Imunoglobulina G/imunologia , Injeções Subcutâneas , Masculino , Pessoa de Meia-Idade , Olea/imunologia , Rinite/imunologiaRESUMO
Summary: Objectives. Evaluate the changes in quality of life of patients with allergic rhinoconjunctivitis (AR), with or without asthma, after one-year treatment with allergen immunotherapy. Methods. This was an observational prospective multicenter study. RQLQ questionnaire and VAS scale to assess treatment satisfaction were used. Impact on AR and asthma was also analyzed. Any adverse reaction was recorded. Results. 127 patients were recruited. Mean values in RQLQ decreased from 2.61 to 1.34 points, reflecting a statistically and clinically significant improvement (p minor 0.01). The percentage of asthmatic patients decreased significantly (p minor 0.01). Mean value of patients' satisfaction was 7.24 (SD = 1.90). Only 11 patients presented systemic reactions (9.17%), none of them serious. Conclusions. One-year AIT treatment significantly increases QoL in patients with AR. Moreover, high patients' satisfaction values were reported, together with an adequate safety profile.
Assuntos
Asma/terapia , Dessensibilização Imunológica/métodos , Qualidade de Vida/psicologia , Rinite Alérgica/terapia , Adolescente , Adulto , Criança , Dessensibilização Imunológica/efeitos adversos , Feminino , Humanos , Masculino , Cooperação do Paciente/estatística & dados numéricos , Satisfação do Paciente , Estudos Prospectivos , Inquéritos e QuestionáriosRESUMO
We report a case of a 50-year-old patient with bisphosphonate-related osteonecrosis of the jaws (BRONJs) whose symptoms included severe pain and hemimandibular paraesthesia. The treatment included resection of necrotic bone and the application of plasma rich in growth factors (PRGF(®)-Endoret(®)). We closed the ulcer in the soft tissue and her pain and paraesthesia improved. One year postoperatively sensitivity was totally recovered, pain was absent and bone was partially regenerated.